Literature DB >> 31144189

STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?

Alexandra G Lopez-Aguiar1, Lauren M Postlewait1, Cecilia G Ethun1, Mohammad Y Zaidi1, Kristen Zhelnin2, Alyssa Krasinskas2, Maria C Russell1, David A Kooby1, Kenneth Cardona1, Bassel F El-Rayes3, Shishir K Maithel4.   

Abstract

BACKGROUND: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are highly vascular neoplasms treated similarly, irrespective of tumor location. The expression of pro-angiogenic factors (STAT3, VEGF, and HIF-1α) and their association with adverse pathologic factors and disease recurrence following resection remains unclear.
METHODS: All patients with non-metastatic GEP-NETs who underwent curative-intent resection from 2000 to 2013 were included. Immunohistochemistry was performed for pro-angiogenic factors, Ki-67 index, and CD31 using tissue microarrays made in triplicate by a pathologist blinded to other clinicopathologic variables. Primary outcome was a 3-year recurrence-free survival (3-yrRFS); secondary outcomes were correlation of pro-angiogenic factors with Ki-67 index, adverse pathologic factors, and CD31 expression, a marker of microvascular density.
RESULTS: Of 144 GEP-NETs resected, STAT3 expression was high in 12 (8%) and low in 132 (92%) pts. High STAT3 expression was associated with worse 3-yrRFS compared to low expression (55% vs 84%; p = 0.003). High VEGF expression had a 3-yrRFS of 76% vs 82% for low expression (p = 0.09). HIF-1α expression was not associated with RFS. Ki-67 ≥ 3% was associated with worse 3-yrRFS (≥ 3%: 51% vs < 3%: 84%; p < 0.001), as was the presence of increased microvascular density (CD31 > median: 75% vs CD31 < median: 86%; p = 0.04). High STAT3 expressing tumors were more likely to have a Ki-67 ≥ 3% (42% vs 7%; p < 0.001). LVI was present in 82% of high STAT3 tumors compared to only 50% with low STAT3 (p = 0.058). CD31 expression was similar between groups (58% vs 49%; p = 0.5).
CONCLUSIONS: In resected GEP-NETs, high STAT3 expression is associated with an increased Ki-67 index, presence of lymphovascular invasion and worse 3-yr RFS. STAT3 may be a novel therapeutic target for patients undergoing resection of high-risk tumors.

Entities:  

Keywords:  CD31; Gastroenteropancreatic neuroendocrine tumors; Ki-67; STAT3

Mesh:

Substances:

Year:  2019        PMID: 31144189     DOI: 10.1007/s11605-019-04261-6

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  3 in total

1.  Resveratrol Suppresses Tumor Progression via Inhibiting STAT3/HIF-1α/VEGF Pathway in an Orthotopic Rat Model of Non-Small-Cell Lung Cancer (NSCLC).

Authors:  Huixia Wang; Ruzhen Jia; Tianle Lv; Mei Wang; Shiwei He; Xia Zhang
Journal:  Onco Targets Ther       Date:  2020-07-21       Impact factor: 4.147

Review 2.  Treatment personalization in gastrointestinal neuroendocrine tumors.

Authors:  Chiara Borga; Gianluca Businello; Sabina Murgioni; Francesca Bergamo; Chiara Martini; Eugenio De Carlo; Elisabetta Trevellin; Roberto Vettor; Matteo Fassan
Journal:  Curr Treat Options Oncol       Date:  2021-02-27

Review 3.  Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms.

Authors:  Javier Pozas; María San Román; Teresa Alonso-Gordoa; Miguel Pozas; Laura Caracuel; Alfredo Carrato; Javier Molina-Cerrillo
Journal:  Int J Mol Sci       Date:  2019-10-08       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.